News releases | Absci Corp

Year

15 Nov / 23

Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Piper Sandler 35 th Annual Healthcare Conference in New York, NY.

14 Nov / 23

Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results

Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties Unveiled AI drug creation pipeline of four wholly-owned assets VANCOUVER, Wash. and NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation

14 Nov / 23

Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases VANCOUVER, Wash. and BARCELONA, Spain, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation

26 Oct / 23

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences in New York, NY.

21 Sep / 23

Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen

VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day on Wednesday, October 4 th , 2023. The program will begin at 9:00 a.m.

06 Sep / 23

Absci to Host R&D Day on October 4, 2023

VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on Wednesday, October 4 th , 2023 in New York City. The program will begin at 9:00 a.m.

28 Aug / 23

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 25 th Annual Global Investment Conference

14 Aug / 23

Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results

Entered into partnership with Google Ventures-backed biotech company to discover innovative new medicines Entered into collaboration with Caltech, supported by the Gates Foundation, to discover affordable HIV therapeutic vaccinations VANCOUVER, Wash. and NEW YORK, Aug.

14 Aug / 23

Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer

Addition of veteran biotech leader to further support Absci’s next stage of growth VANCOUVER, Wash., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation , a generative AI drug creation company, announced today that Zach Jonasson, Ph.D., has been appointed Chief Financial Officer (CFO) and Chief

10 Aug / 23

Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

VANCOUVER, Wash., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation company, today announced that leading researchers at the California Institute of Technology (Caltech) in conjunction with Absci, a leader in AI drug creation, received a grant from

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 26